Review considerations for MOUD initiation and follow-up, including lab guidelines, and clinical management of patients with continued use (e.g., fentanyl, novel synthetic opioids), overdose risk, poly-substance use, and comorbid mental health conditions.

Facilitator: Sherry Larkins, PhD, Director of International Programs and Research Sociologist, Integrated Substance Abuse Programs at the University of California, Los Angeles – Semel Institute for Neuroscience and Human Behavior

Cost: No fee

Target Audience: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, licensed counselors, social workers, clinical administrators, and healthcare teams.

Credit Designations Available: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, and Interprofessional Continuing Education (IPCE) credit. Note: A Certificate of Attendance which acknowledges 1 hour of participation is also available (0 CE).

Webinar Description: Once we’ve successfully managed the organizational and clinical steps to implement treatment for patients with OUD, we need to ensure continued access to high-quality care for our patients, including those with on-going challenges. What does treatment look like for patients on their first visit and follow-up visits? This session will discuss key considerations for patient initiation (induction) and on-going visits, including lab guidelines. We will additionally address the clinical management of patients with continued opioid use (e.g., fentanyl, novel synthetic opioids), poly-substance use, overdose risk, and comorbid trauma and mental health conditions.

Educational Objectives:

• Review and consider intake assessment / lab guidelines and practice.
• Determine key considerations for patient initiation visit (induction) and follow-up visits, and patient stabilization. 
• Explain considerations in managing continued opioid use (e.g., fentanyl, novel synthetic opioids, etc.), poly-substance use and comorbid trauma and mental health conditions.
• Discuss Harm Reduction strategies to decreased overdose risk.

Accreditation Statement:
In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements:

Physicians
American Academy of Addiction Psychiatry designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Nurse Practitioners
American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP’s Joint Accreditation provider #4008192. This activity is approved for up to 1 CNE credits.

PAs
American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Other Health Professionals and Other Learners
Participants will receive a certificate stating this program is designated for 1 AMA PRA Category 1 Credits™. This credit is accepted by the AANP and the AAPA.

All Learners
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education credits for learning and change.